PT Medikaloka Hermina (HEAL) Fundamentals 2026 — P/E 31.4x, Revenue Analysis | SniperIQ
PT Medikaloka Hermina (HEAL) is a ID-listed Healthcare company in Medical - Care Facilities with a market capitalization of Rp12.71T, trading at Rp830.00 on the JKT. This SniperIQ fundamentals page covers PT Medikaloka Hermina's valuation (P/E 31.4x, P/B 2.2x), profitability (net margin 5.6%), revenue (Rp7.13T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is PT Medikaloka Hermina's market cap?
PT Medikaloka Hermina (HEAL) has a market capitalization of approximately Rp12.71T, trading at Rp830.00 on the JKT. Market cap moves with the live share price.
What is PT Medikaloka Hermina's P/E ratio?
PT Medikaloka Hermina's trailing twelve-month P/E ratio is 31.4x, with a price-to-book (P/B) of 2.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is PT Medikaloka Hermina?
PT Medikaloka Hermina runs a net profit margin of 5.6%, a gross margin of 31.2%, and an operating margin of 12.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does PT Medikaloka Hermina generate?
PT Medikaloka Hermina reported revenue of Rp7.13T for fiscal year 2025, with net income of Rp429.5B and earnings per share (EPS) of 28.4. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does PT Medikaloka Hermina pay a dividend?
PT Medikaloka Hermina offers a trailing dividend yield of about 1.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is PT Medikaloka Hermina financially healthy?
PT Medikaloka Hermina carries a debt-to-equity ratio of 0.61x and a current ratio of 1.36x, with a market beta of -0.19. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is PT Medikaloka Hermina a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PT Medikaloka Hermina (HEAL) the key facts are: market cap Rp12.71T, P/E 31.4x, revenue Rp7.13T, 52-week range 760-1775. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track PT Medikaloka Hermina's full fundamentals live
Get PT Medikaloka Hermina's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.